Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | QDPR | P09417 | 3/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16154956 | 0.91 | HTR2C (0.50) | HTR2CSIGMAR1QDPRCTSLCTSB | |
| SCHEMBL17660298 | 0.82 | SIGMAR1 (0.65) | HTR2CSIGMAR1QDPRCTSLCTSB | |
| SCHEMBL4790435 | 0.79 | HTR2C (0.66) | HTR2CSIGMAR1QDPRHTR6HTR7 | |
| SCHEMBL30431801 | 0.79 | HTR2C (0.66) | HTR2CSIGMAR1QDPRHTR6HTR7 | |
| SCHEMBL13086837 | 0.78 | SIGMAR1 (0.46) | HTR2CSIGMAR1QDPRCTSLCTSB | |
| SCHEMBL30716248 | 0.78 | SIGMAR1 (0.46) | HTR2CSIGMAR1QDPRCTSLCTSB | |
| SCHEMBL22144414 | 0.78 | HTR2C (0.56) | HTR2CSIGMAR1QDPRCTSLCTSB | |
| Hydrochloric Acid SCHEMBL9311920 | 0.78 | HTR2C (0.67) | HTR2CSIGMAR1QDPRHTR6HTR7 | |
| SCHEMBL4791120 | 0.77 | SIGMAR1 (0.79) | HTR2CSIGMAR1QDPRCTSLCTSB | |
| SCHEMBL21228136 | 0.76 | HTR2C (0.66) | HTR2CSIGMAR1QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020132561-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-2770995-B1 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME (US) | 2019-01-02 | — | — | EP | disclosed |
| US-9440958-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2016-09-13 | — | — | US | disclosed |
| US-9273040-B2 | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2015-01-22 | — | — | US | disclosed |
| US-20140303143-A1 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC | 2014-10-09 | — | — | US | disclosed |
| US-8853243-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2014-10-07 | — | — | US | disclosed |
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-7973041-B2 | Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. | INCYTE CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1678167-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Incyte Corporation (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | INCYTE CORPORATION | 2005-11-10 | — | — | US | disclosed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005037826-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP14, MMP9 | HTR2C 2401/4885SIGMAR1 3327/4885QDPR 890/4885 |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP2, MMP14 | HTR2C 2380/4885SIGMAR1 3105/4885QDPR 868/4885 |
| US-20140303143-A1 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | SCN7A, SCN1A, CACNA1E | HTR2C 476/4885SIGMAR1 663/4885QDPR 1646/4885 |
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | MMP9, MMP17, MMP25 | HTR2C 2955/4885SIGMAR1 4814/4885QDPR 2491/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | HTR2C 2239/4885SIGMAR1 3239/4885QDPR 883/4885 |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | HTR2C 2380/4885SIGMAR1 3105/4885QDPR 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.